Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

✍ Scribed by Motzer, R. J.; Nosov, D.; Eisen, T.; Bondarenko, I.; Lesovoy, V.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Alyasova, A.; Harza, M.; Kogan, M.; Alekseev, B. Y.; Sternberg, C. N.; Szczylik, C.; Cella, D.; Ivanescu, C.; Krivoshik, A.; Strahs, A.; Esteves, B.; Berkenblit, A.; Hutson, T. E.

• Book ID: 125850038
• Publisher: American Society of Clinical Oncology
• Year: 2013
• Tongue: English
• Weight: 196 KB
• Volume: 31
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/JCO.2012.47.4940